Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/367 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME11548225
PMID: | 11548225
LR: | 20061115
CED: | 20010910
DCO: | 20010920
Autoren: | Müller-Fassbender H; Bach GL; Haase W; Rovati LC; Setnikar I
Titel: | Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee.
Quelle: | Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society; VOL: 2 (1); p. 61-9 /199403/
PM: | Print
SU: | IM
Sprache: | English
CY: | England
JID: | 9305697
ISSN: | 1063-4584
Institution: | Rheumazentrum, Bad Abbach, Germany.
DT: | Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
Schlagwörter
CT: | ADMINISTRATION, ORAL; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/*administration & dosage; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/adverse effects; FEMALE; GLUCOSAMINE/*administration & dosage; GLUCOSAMINE/adverse effects; HUMANS; IBUPROFEN/*administration & dosage; IBUPROFEN/adverse effects; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE/*drug therapy; PAIN/prevention & control; PAIN MEASUREMENT; TREATMENT OUTCOME
CTG: | APPLIKATION, ORALE; ERWACHSENER; ALTE MENSCHEN; ANTIPHLOGISTIKA, NICHTSTEROIDALE/*Verabreichung & Dosierung; ANTIPHLOGISTIKA, NICHTSTEROIDALE/unerwünschte Nebenwirkungen; WEIBLICH; GLUCOSAMIN/*Verabreichung & Dosierung; GLUCOSAMIN/unerwünschte Nebenwirkungen; MENSCH; IBUPROFEN/*Verabreichung & Dosierung; IBUPROFEN/unerwünschte Nebenwirkungen; MÄNNLICH; MENSCHEN IM MITTLEREN LEBENSALTER; OSTEOARTHROSE, KNIE/*Arzneimitteltherapie; SCHMERZEN/Verhütung & Bekämpfung; SCHMERZMESSUNG; BEHANDLUNGSERGEBNIS
TE: | Anti-Inflammatory Agents, Non-Steroidal; Ibuprofen/15687-27-1; Glucosamine/3416-24-8
CR: | 15687-27-1; 3416-24-8
AB: | Glucosamine sulfate is able to stimulate proteoglycan synthesis by chondrocytes and has mild anti-inflammatory properties. In clinical trials, glucosamine sulfate was more effective than placebo in controlling the symptoms of osteoarthritis (OA). In order to better characterize this therapeutic activity, we conducted a randomized, double-blind, parallel-group study of glucosamine sulfate 500 mg t.i.d. vs ibuprofen 400 mg t.i.d., orally for 4 weeks. The study included 200 hospitalized patients with active OA of the knee, symptoms for at least 3 months and a Lequesne's index of at least 7 points. Patients were evaluated weekly. Response was defined as a reduction in the Lequesne's index by at least 2 points if the enrollment value was higher than 12 points, or by at least 1 point if the enrollment value was 12 or less points, together with a positive overall assessment by the investigator. The improvement tended to be sooner under ibuprofen (48% responders vs 28% after the 1st treatment week; P = 0.06, Fisher's Exact test), but there was no difference from the 2nd week onward, with a success rate of 52% in the ibuprofen group and of 48% in the glucosamine group (P = 0.67) at the end of treatment. The average Lequesne's index at enrollment was around 16 points and decreased by over 6 points in both groups, again with the above described trend. On the other hand, 35% of patients on ibuprofen reported adverse events, mainly of gastrointestinal origin, vs 6% adverse events with glucosamine (P < 0.001, Fisher's Exact test). The number of adverse event related drop-outs was different between the two groups (7% vs 1%, respectively; P = 0.035). Glucosamine sulfate was therefore as effective as ibuprofen on symptoms of knee OA. These data confirm glucosamine sulfate as a safe symptomatic Slow Acting Drug for OA.

» Volltext »
» Fenster schließen »